Eliquis Offered to Cash-Paying Patients at More Than 40% Discount to Current List Price, Sotyktu at More Than 80% Discount to Current List Price PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb ...
Bristol Myers Squibb (NYSE: BMY) today announced an expansion of its direct-to-patient offerings, providing eligible U.S. patients with steeply discounted prices for Eliquis ® (apixaban) and Sotyktu ® ...
Beginning January 2026, Sotyktu, BMS’ medicine for moderate-to-severe plaque psoriasis, will be offered through the new BMS Patient Connect platform, which follows the launch of our Bristol Myers ...
Bristol Myers Squibb announced an expansion of its direct-to-patient offerings, providing eligible US patients with steeply discounted prices for Eliquis (apixaban) and Sotyktu (deucravacitinib).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results